



Innovations delivered in 2022 and planned for 2023

Embase is a complete biomedical database where you can access rich content, connect concepts, easily build queries and maintain current awareness.

Building a better database for you

In 2022, Embase innovated in every way, expanding and improving our content, search, email alerts, and the Emtree taxonomy.

Here are the highlights:

Content expanded by over 20% in number of records

- Journals focused on biomedical engineering and medical devices have been added to Embase
- Article preprints from MedRxiv and BioRxiv have been added, providing access to the earliest possible biomedical information for systematic reviews, KOL identification, competitive intelligence

Improved ease-of-use and search

- Simplified Citation search and Records detail page, improved Quick search page and PICO search page leading to better user experience
- Labelling of Open access journals and option to browse and select them only
- Improved Email Alert management system
- Introduction of linking between preprints and the published articles


Emtree development

- COVID-19: Addition of new variants, new approved treatments and clinical trial data
- Medical devices: Continued expansion of approved FDA devices (over 400 new device tradenames), addition of new GMDN terms and linkage with FDA GUDID

Standardized data delivery by development of new DAAS solution

- Delivery of a common single schema for the full corpus and all the subsequent data updates
- Enable permission-based access to the most up to date Embase content and the regular updates as XML in the same location





New developments coming this year

In 2023, Embase will continue to expand content, enlarge Emtree taxonomy, improve user experience and usage reporting, and innovate.

Look out for these new features and improvements:

PubMed-to-Embase query translation tool

A new feature will support the needs of information specialists, systematic reviewers, pharmacovigilance experts, and all other users that are required to translate their PubMed queries into Embase searches. This tool will also explain how the Embase search syntax works in comparison with the one in PubMed.



Providing COUNTER compliant usage statistics

COUNTER COP5 reports will be available for download directly by our customers via the Elsevier E-PIC platform, providing usage data that is consistent, comparable, and compliant.

New design of results page, clipboard and saved search page

The new design of these pages will allow novice users to quickly master how to use and get the most out of the Results Page, Clipboard and Saved search, while keeping the functionalities that our power users (e.g. information specialists) are using.

Streamlining data delivery by development of new Embase API

The new API will standardize Embase data available via different channels (DaaS, API) into one common schema. This change will decouple customer-facing API from [Embase.com](https://www.elsevier.com/embase.com), leading to improved speed of data retrieval. The Embase team will provide users with clear and complete documentation on how to use new Embase API to ensure a smooth transition.



For more information, visit:

elsevier.com/solutions/embase-biomedical-research

Embase is a trademark of Elsevier Inc.
Copyright © 2023 Elsevier B.V. February 2023

